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Introduction: Alzheimer is a brain dysfunctional disease which could destroy the 
cognition and learning capabilities of the patient. Rivastigmine is an acetylcholine 
esterase inhibitor which can improve brain function in both Alzheimer and 
Parkinson's diseases. Hereby, we prepared niosomal formulations of rivastigmine for 
better penetration of this drug to brain. 
Methods and Results: Sorbitan esters (Span 20, 40, 60 and 80), their water-soluble 
derivatives (Tween 20, 40, 60 and 80) and cholesterol were used for preparation of 
niosomes by film hydration method. Deionized water was used as hydration 
medium. Volume diameter, drug release profile, rivastigmine encapsulation 
efficiency and vesicular stability were evaluated. All used surfactant combinations 
formed round and tubular multilamellar vesicles (MLVs). Single mode size 
distribution, high encapsulation efficiency (more than 70%), good stability of 
vesicles depicted as unchanged size and finally, diffusion-based release profiles were 
shown for many of niosomal formulations. 
Conclusions: Incorporation of rivastigmine into bilayer assemblies of niosomes 
compromises a good candidate for new drug delivery system which further studied 
in animal models will prove or reject its applicability in human.  
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